Oslo, August 25, 2023: A consumer brand in Australia using Aker BioMarine’s Superba Boost krill oil has been included on the Australia Register of Therapeutic Goods (ARTG) as an ‘assessed listed’ medicine with two specific indications:
1. Decrease/reduce/relieve knee pain and stiffness in mild to moderate osteoarthritis
2. Increase knee physical function in mild to moderate osteoarthritis
The ‘assessed listed’ status means that the product has been reviewed by the country’s regulatory body to assess the efficacy of its health claims.
With its newly secured approval, the brand can now add information about the health benefits of Suberba Boost to the product label and include these messages in consumer advertising. The approved product claims are exclusive to the brand for the next five years.
“This is a strong testament to the effectiveness of our Superba krill oil, and will support us in building the market for Superba krill oil, primarily in the Australian market but also in other markets.”, says Matts Johansen, CEO Aker BioMarine.
This is the second health claim exclusively for Superba Krill oil, the other being the health claim received in South Korea in 2023.
Information about clinical trials
Australia’s national science agency, CSIRO, recently ran a clinical trial over six months to evaluate the impact of krill oil on osteoarthritis of the knee. The study evaluated 235 adults between 40 to 65 years of age who suffer from mild to moderate knee pain. The results showed that not only did Superba Boost significantly reduce the pain, but it also helped improve stiffness and physical function in the knees.
For further information, please contact
Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com
About Superba Krill
SuperbaTM Krill is a pure and natural source of the health-promoting EPA & DHA omega-3 essential fatty acids and the naturally occurring antioxidant, astaxanthin. The uniqueness of SuperbaTM Krill is that the omega-3 fatty acids are provided in phospholipid form. In vitro, in vivo and human clinical research has demonstrated the safety and efficacy of SuperbaTM Krill.
About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.